Fidelity International’s Heron Therapeutics HRTX Stock Holding History

Fidelity International’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-481,200	Closed	-$7.13M	–	992
2020 Q3	$7.13M	Sell	481,200 -950,835	-66%	-$14.8M	0.01%	514
2020 Q2	$21.1M	Sell	1,432,035 -1,039,208	-42%	-$17.1M	0.03%	382
2020 Q1	$29M	Buy	2,471,243 +296,078	+14%	+$5.57M	0.05%	303
2019 Q4	$51.1M	Buy	2,175,165 +377,940	+21%	+$8.36M	0.07%	255
2019 Q3	$33.2M	Buy	1,797,225 +283,590	+19%	+$5.22M	0.05%	301
2019 Q2	$28.1M	Sell	1,513,635 -272,673	-15%	-$5.45M	0.04%	326
2019 Q1	$43.7M	Sell	1,786,308 -481,546	-21%	-$12.6M	0.07%	253
2018 Q4	$58.8M	Sell	2,267,854 -795,529	-26%	-$21.9M	0.1%	206
2018 Q3	$97M	Buy	3,063,383 +103,224	+3%	+$3.84M	0.14%	170
2018 Q2	$115M	Buy	+2,960,159	New	+$94.2M	0.17%	151

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Fidelity International's HRTX Position: Q4 2020 in Review

Fidelity International sold out of Heron Therapeutics (HRTX) in Q4 2020, closing a stake of 481,200 shares — an estimated $7.13M sold.

Fidelity International first reported a position in HRTX in Q2 2018 and held it in 10 quarters. The position peaked at $115M in Q2 2018. 189 funds tracked by Wall St. Rank hold HRTX as of Q4 2020.

Fidelity International reported no remaining Heron Therapeutics position as of Q4 2020 after selling out during the quarter.
Fidelity International sold 481,200 Heron Therapeutics shares in Q4 2020, an estimated $7.13M.
Fidelity International first reported a position in Heron Therapeutics in Q2 2018 and held it in 10 quarters.
Fidelity International's Heron Therapeutics position peaked at $115M in Q2 2018.
189 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2020.

Based on Fidelity International's 13F filing for Q4 2020, filed 8 Feb 2021.